Infliximab therapy for patients with ankylosing spondylitis: on-demand or continuous treatment?

Abstract

Original article Breban M et al. (2008) Maintenance of infliximab treatment in ankylosing spondylitis: results of a one-year randomized controlled trial comparing systematic versus on-demand treatment. Arthritis Rheum 58: 88-97

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010

“…Regular treatment with infliximab was more effective than ‘on-demand’ treatment for AS (category A evidence309 310). …”

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011

“…Regular therapy with infliximab was more effective than ‘on demand’ therapy for treating AS (category A evidence381 382). In a head-to-head comparison trial of a conventional DMARD (sulfasalazine) with a TNF inhibitor (etanercept), the latter was more effective (category A evidence,295 383).…”